SRR934962
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.631
- ANGIOGENESIS+0.604
- E2F_TARGETS+0.601
- G2M_CHECKPOINT+0.598
- TNFA_SIGNALING_VIA_NFKB+0.577
- IL6_JAK_STAT3_SIGNALING+0.559
- INTERFERON_ALPHA_RESPONSE+0.525
- INTERFERON_GAMMA_RESPONSE+0.514
- TGF_BETA_SIGNALING+0.503
- MITOTIC_SPINDLE+0.462
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.452
- KRAS_SIGNALING_DN-0.420
- BILE_ACID_METABOLISM-0.257
- OXIDATIVE_PHOSPHORYLATION-0.226
- SPERMATOGENESIS-0.185
- PEROXISOME-0.135
- HEME_METABOLISM-0.107
- XENOBIOTIC_METABOLISM-0.107
- MYOGENESIS-0.058
- FATTY_ACID_METABOLISM-0.044
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934760 | — | — | 0.974 |
| 2 | SRR934881 | — | — | 0.973 |
| 3 | SRR934864 | — | — | 0.963 |
| 4 | D5191F3D-028E-401C-927E-483F6884BE39 | — | — | 0.963 |
| 5 | SRR934753 | — | — | 0.962 |
| 6 | SRR934934 | — | — | 0.962 |
| 7 | SRR934747 | — | — | 0.954 |
| 8 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.949 |
| 9 | SRR934932 | — | — | 0.949 |
| 10 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.947 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.631 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.604 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.601 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.598 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.577 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.559 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.525 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.514 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.503 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.462 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.455 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.454 | Idelalisib | — uncovered |
| HYPOXIA | 0.427 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.414 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.402 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.401 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.397 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.396 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.395 | Inavolisib | — uncovered |
| APOPTOSIS | 0.388 | Idelalisib | — uncovered |